Takeda Pharmaceuticals has entered into a deal with US-based DSI Renal for the supply of its OMONTYS (peginesatide) injection, designed for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. ...
Tags: OMONTYS injection, anemia, chronic kidney disease, CKD patients
Affymax has earned $50m development milestone payment from Takeda Pharmaceutical Company for the US approval of OMONTYS (peginesatide) injection. The company has also received another $5m milestone payment, which was triggered by the ...
Takeda Pharmaceuticals America (TPA) has signed a contract to supply Omontys (peginesatide) injection to Fresenius Medical Care North America and certain of its affiliates. Omontys (peginesatide) injection is a synthetic, pegylated, ...
Takeda Pharmaceuticals USA (TPUSA) and Affymax have announced supply agreement with US Renal Care for Omontys (peginesatide) injection in the US. Under the agreement, US Renal Care will purchase Omontys for use within its organization and ...
Tags: Medicine, Omontys Injection
Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS (peginesatide) injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The once-monthly erythropoiesis-stimulating ...
The Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code (Q-code) for Affymax's Omontys (peginesatide) injection. Omontys is a once-monthly erythropoiesis-stimulating agent (ESA) for anemia ...
Tags: omontys, peginesatide, CKD